002020 京新药业
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入923,034-3.46%4,069,3614,158,5513,998,8353,779,846
减:营业总成本738,161-6.06%3,228,4483,369,9443,367,0363,084,849
    其中:营业成本451,517-9.68%2,028,6312,080,3481,976,4881,766,149
               财务费用1,553-112.49%(45,160)(64,434)(53,828)(72,321)
               资产减值损失(7,953)-256.67%(47,434)(12,808)(21,145)(20,898)
公允价值变动收益9411,288.46%9,471(42,367)36,77123,952
投资收益619-85.95%17,1098,9576,44119,416
    其中:对联营企业和合营企业的投资收益----(470)(658)(6,042)(4,165)
营业利润194,1320.49%862,655843,606714,059756,616
利润总额191,374-0.95%864,326843,980708,041750,316
减:所得税费用25,224-9.38%97,658124,85484,62382,493
净利润166,1500.46%766,668719,126623,418667,823
减:非控股权益947-54.66%8,6897,1654,5205,569
股东净利润165,2031.17%757,979711,961618,898662,254

市场价值指针
每股收益 (元) *0.2000.00%0.9200.8300.7200.770
每股派息 (元) *----0.3500.3500.3000.300
每股净资产 (元) *7.0777.11%6.7756.9336.4025.977
审计意见 #--标准无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容